Metraipolis › archive › dc_e80cda18fa2e

Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors — Europe PMC PMID:42959597

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42959597
DOI: 10.1016/j.omton.2026.201357
License (as archived): solo-consultazione
Archived: 2026-11-01T01:04:10.019Z
SHA-256 of the archived text: cbfbbf2ad3c7d78b8d2768c98612206a176adbd0f8aea2115d8a45975a5dc40f
Stable URL of this page: https://metraipolis.com/documento/dc_e80cda18fa2e

How to cite

Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors — Europe PMC PMID:42959597 — Europe PMC (en), https://europepmc.org/article/MED/42959597 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e80cda18fa2e (Metraipolis archive dc_e80cda18fa2e, sha256 cbfbbf2ad3c7d78b8d2768c98612206a176adbd0f8aea2115d8a45975a5dc40f)

BibTeX

@misc{dce80cda18fa2e,
  title = {Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors — Europe PMC PMID:42959597},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42959597},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e80cda18fa2e; sha256 cbfbbf2ad3c7d78b8d2768c98612206a176adbd0f8aea2115d8a45975a5dc40f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42959597. Agents can read the archived copy with the MCP tool read_document.